Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Read-Gene

WSE:RDG
Snowflake Description

Adequate balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
RDG
WSE
PLN13M
Market Cap
  1. Home
  2. PL
  3. Pharmaceuticals & Biotech
Company description

Read-Gene S.A. engages in the detection, prevention, and treatment of various types of malignant tumors. The last earnings update was 136 days ago. More info.


Add to Portfolio Compare Print
  • Read-Gene has significant price volatility in the past 3 months.
RDG Share Price and Events
7 Day Returns
-17.4%
WSE:RDG
-7.2%
PL Biotechs
-1.5%
PL Market
1 Year Returns
37.3%
WSE:RDG
-10.5%
PL Biotechs
-33%
PL Market
RDG Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Read-Gene (RDG) -17.4% 29.5% 72.7% 37.3% -20.8% -25%
PL Biotechs -7.2% 18.2% -18.3% -10.5% -38.5% -46.1%
PL Market -1.5% -19.6% -27.9% -33% -37.3% -38.2%
1 Year Return vs Industry and Market
  • RDG outperformed the Biotechs industry which returned -10.5% over the past year.
  • RDG outperformed the Market in Poland which returned -33% over the past year.
Price Volatility
RDG
Industry
5yr Volatility vs Market
Related Companies

RDG Value

 Is Read-Gene undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Read-Gene. This is due to cash flow or dividend data being unavailable. The share price is PLN1.14.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Read-Gene's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Read-Gene's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
WSE:RDG PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in PLN PLN0.07
WSE:RDG Share Price ** WSE (2020-03-27) in PLN PLN1.14
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 33.99x
Poland Market PE Ratio Median Figure of 421 Publicly-Listed Companies 9.24x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Read-Gene.

WSE:RDG PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= WSE:RDG Share Price ÷ EPS (both in PLN)

= 1.14 ÷ 0.07

16.58x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Read-Gene is good value based on earnings compared to the Europe Biotechs industry average.
  • Read-Gene is overvalued based on earnings compared to the Poland market.
Price based on expected Growth
Does Read-Gene's expected growth come at a high price?
Raw Data
WSE:RDG PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 16.58x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.55x
Poland Market PEG Ratio Median Figure of 103 Publicly-Listed Companies 0.73x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Read-Gene, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Read-Gene's assets?
Raw Data
WSE:RDG PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in PLN PLN0.33
WSE:RDG Share Price * WSE (2020-03-27) in PLN PLN1.14
Poland Biotechs Industry PB Ratio Median Figure of 7 Publicly-Listed Biotechs Companies 2.65x
Poland Market PB Ratio Median Figure of 640 Publicly-Listed Companies 0.84x
WSE:RDG PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= WSE:RDG Share Price ÷ Book Value per Share (both in PLN)

= 1.14 ÷ 0.33

3.5x

* Primary Listing of Read-Gene.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Read-Gene is overvalued based on assets compared to the PL Biotechs industry average.
X
Value checks
We assess Read-Gene's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Read-Gene has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

RDG Future Performance

 How is Read-Gene expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Read-Gene has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
21%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Read-Gene expected to grow at an attractive rate?
  • Unable to compare Read-Gene's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Read-Gene's earnings growth to the Poland market average as no estimate data is available.
  • Unable to compare Read-Gene's revenue growth to the Poland market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
WSE:RDG Future Growth Rates Data Sources
Data Point Source Value (per year)
Europe Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 21%
Europe Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 16.6%
Poland Market Earnings Growth Rate Market Cap Weighted Average 12%
Poland Market Revenue Growth Rate Market Cap Weighted Average 4.6%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
WSE:RDG Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in PLN Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
WSE:RDG Past Financials Data
Date (Data in PLN Millions) Revenue Cash Flow Net Income *
2019-09-30 8 -3 0
2019-06-30 8 -3 0
2019-03-31 7 -2 1
2018-12-31 7 0 1
2018-09-30 3 2 -1
2018-06-30 4 2 -1
2018-03-31 4 -2 0
2017-12-31 5 -1 0
2017-09-30 6 1 -1
2017-06-30 5 0 -1
2017-03-31 6 4 0
2016-12-31 5 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Read-Gene is high growth as no earnings estimate data is available.
  • Unable to determine if Read-Gene is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
WSE:RDG Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Read-Gene Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

WSE:RDG Past Financials Data
Date (Data in PLN Millions) EPS *
2019-09-30
2019-06-30
2019-03-31
2018-12-31 0.07
2018-09-30
2018-06-30
2018-03-31
2017-12-31 0.00
2017-09-30
2017-06-30
2017-03-31
2016-12-31 -0.04

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Read-Gene will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Read-Gene's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Read-Gene's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Read-Gene's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Read-Gene's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Read-Gene has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

RDG Past Performance

  How has Read-Gene performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Read-Gene's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Read-Gene does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Read-Gene's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Read-Gene's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Read-Gene's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Read-Gene Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

WSE:RDG Past Revenue, Cash Flow and Net Income Data
Date (Data in PLN Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 8.31 -0.05 2.08
2019-06-30 7.97 0.33 2.08
2019-03-31 7.24 0.57 2.08
2018-12-31 7.12 0.81 2.08
2018-09-30 3.38 -0.69 1.95
2018-06-30 3.60 -0.75 1.95
2018-03-31 4.13 -0.45 1.95
2017-12-31 4.82 0.05 1.95
2017-09-30 6.00 -1.27
2017-06-30 5.38 -1.18
2017-03-31 5.85 -0.33 3.49
2016-12-31 5.20 -0.49
2016-09-30 3.85 -0.38 2.57
2016-06-30 3.56 -0.15 2.57
2016-03-31 1.71 -0.72 2.05
2015-12-31 2.19 -0.68 2.57
2015-09-30 1.48 -0.59 0.94
2015-06-30 1.27 -0.52 0.94
2015-03-31 1.16 -0.58 0.94
2014-12-31 0.77 -0.78 0.94
2014-09-30 0.36 -0.83 0.60
2014-06-30 0.38 -0.88 0.60
2014-03-31 0.27 -0.90 0.60
2013-12-31 0.27 -0.77 0.60
2013-09-30 0.34 -0.63 0.41
2013-06-30 0.43 -0.42 0.41
2013-03-31 0.50 -0.33 0.41

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Read-Gene has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • Read-Gene used its assets less efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • It is difficult to establish if Read-Gene improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Read-Gene's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Read-Gene has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

RDG Health

 How is Read-Gene's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Read-Gene's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Read-Gene's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Read-Gene's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Read-Gene's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Read-Gene has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Read-Gene Company Filings, last reported 5 months ago.

WSE:RDG Past Debt and Equity Data
Date (Data in PLN Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 1.78 0.00 4.15
2019-06-30 2.61 0.00 4.08
2019-03-31 3.25 0.00 5.20
2018-12-31 3.84 0.00 5.01
2018-09-30 1.65 0.00 2.42
2018-06-30 2.12 0.00 2.85
2018-03-31 3.05 0.00 2.62
2017-12-31 3.03 0.42 3.41
2017-09-30 2.52 0.00 3.15
2017-06-30 4.59 0.00 3.03
2017-03-31 4.34 0.00 3.25
2016-12-31 2.98 0.58 3.79
2016-09-30 3.07 0.00 0.85
2016-06-30 3.57 0.00 0.92
2016-03-31 3.05 0.00 0.14
2015-12-31 3.47 0.74 0.30
2015-09-30 3.97 0.00 0.82
2015-06-30 4.19 0.00 0.33
2015-03-31 2.41 0.00 1.08
2014-12-31 4.15 0.89 0.23
2014-09-30 2.45 0.00 0.04
2014-06-30 2.97 0.00 0.01
2014-03-31 2.64 0.00 0.01
2013-12-31 4.94 1.05 0.03
2013-09-30 3.59 0.00 0.05
2013-06-30 3.40 0.00 0.02
2013-03-31 -0.10 0.00 -0.09
  • Read-Gene has no debt.
  • Read-Gene has no debt compared to 5 years ago when it was 0.4%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Read-Gene has sufficient cash runway for 1.4 years based on current free cash flow.
  • Read-Gene has less than a year of cash runway if free cash flow continues to grow at historical rates of 2.6% each year.
X
Financial health checks
We assess Read-Gene's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Read-Gene has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

RDG Dividends

 What is Read-Gene's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Read-Gene dividends.
If you bought PLN2,000 of Read-Gene shares you are expected to receive PLN0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Read-Gene's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Read-Gene's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
WSE:RDG Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Poland Market Average Dividend Yield Market Cap Weighted Average of 195 Stocks 6%
Poland Minimum Threshold Dividend Yield 10th Percentile 1.6%
Poland Bottom 25% Dividend Yield 25th Percentile 3.2%
Poland Top 25% Dividend Yield 75th Percentile 8.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Read-Gene has not reported any payouts.
  • Unable to verify if Read-Gene's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Read-Gene's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Read-Gene has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Read-Gene's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.6%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Read-Gene afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Read-Gene has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

RDG Management

 What is the CEO of Read-Gene's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jan Lubinski
CEO Bio

Prof. Jan Lubinski serves as President of the Management Board at Read-Gene SA. Prof. Lubinski served as the Chief Executive Officer of Read-Gene SA. Prof. Lubinski is one of the most famous geneticists / oncologists in Poland. Prof. Lubinski is the founder and the Head of International Hereditary Cancer in Szczecin. He was a visiting scientist at Pasteur Institute in Paris, at the Wistar Institute and at the Jefferson Cancer Institute in Philadelphia. In 1996 he was promoted to Associate Professor at the Pomeranian Medical University in Szczecin. In 1997 he became a member of an Expert Board in Europe and Africa within the framework of Familial Cancer and Prevention International Union Against Cancer (UICC) programme. He was the organizer of a screening examination program in the area of hereditary cancer detection for people in Zachodniopomorskie Region of Poland encompassing a population of 1.5 million. Since 2006, he has been a Member of Board of European Society of Human Genetics. He serves as a Member of Scientific Advisory Board at KCR Biotechnology. He served as a Member of Scientific Advisory Board at Selvita S.A. He also serves as a member of the Biotechnology Committee of the Polish Academy of Sciences and Human Genetics and the Molecular Pathology Committee of Polish Academy of Sciences. He is the author of around 200 papers on clinical and molecular genetics of cancers and the author and coordinator of a few EU projects (Development of Polish Network of Hereditary Cancer Centres, Development of Cancer Family Syndrome Registries in Eastern Europe). He is the editor of a journal published under auspices of UICC - Hereditary Cancer in Clinical Practice and since 1998 the Polish National Consultant of Clinical Genetics. He holds a PhD from the Pomeranian Medical University in Szczecin.

CEO Compensation
  • Insufficient data for Jan to compare compensation growth.
  • Insufficient data for Jan to establish whether their remuneration is reasonable compared to companies of similar size in Poland.
Management Team

Jan Lubinski

TITLE
President of the Management Board

Karolina Ertmanska

TITLE
Administration & Finance Director
Board of Directors

Proper Ziemianim

TITLE
Chairman of the Supervisory Board

Tomasz Huzarski

TITLE
Vice Chairman of the Supervisory Board

Adam Gliszczynski

TITLE
Member of the Supervisory Board

Jacek Gronwald

TITLE
Member of the Supervisory Board

Dariusz Wiecaszek

TITLE
Member of the Supervisory Board

Chomczynski Piotr

TITLE
Member of the Advisory Board

Burn John

TITLE
Member of the Advisory Board

Gardovskis Janis

TITLE
Member of the Advisory Board

Yannoukakos Drakoulis

TITLE
Member of the Advisory Board

MacKay James

TITLE
Member of the Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (PLN) Value (PLN)
X
Management checks
We assess Read-Gene's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Read-Gene has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

RDG News

Simply Wall St News

The Read-Gene (WSE:RDG) Share Price Is Down 28% So Some Shareholders Are Getting Worried

But in truth the last year hasn't been good for the share price. … See our latest analysis for Read-Gene We don't think Read-Gene's revenue of zł3,364,592 is enough to establish significant demand. … But since the share price has dived -28% in the last year, it looks like some investors think it's time to abandon ship, so to speak.

Simply Wall St -

What Kind Of Shareholder Appears On The Read-Gene S.A.'s (WSE:RDG) Shareholder Register?

(WSE:RDG) have power over the company. … Read-Gene is not a large company by global standards. … institutions don't own shares in the company.

Simply Wall St -

Does Read-Gene S.A. (WSE:RDG) Have A High Beta?

Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … Any stock with a beta of greater than one is considered more volatile than the market, while those with a beta below one are either less volatile or poorly correlated with the market.

Simply Wall St -

How Much Of Read-Gene S.A. (WSE:RDG) Do Insiders Own?

Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … Read-Gene is a smaller company with a market capitalization of zł6.0m, so it may still be flying under the radar of many institutional investors. … institutions don't own shares in the company.

Simply Wall St -

Does Market Volatility Impact Read-Gene SA's (WSE:RDG) Share Price?

Beta is a widely used metric to measure a stock's exposure to market risk (volatility). … Before we go on, it's worth noting that Warren Buffett pointed out in his 2014 letter to shareholders that 'volatility is far from synonymous with risk.' Having said that, beta can still be rather useful. … A stock with a beta greater than one is more sensitive to broader market movements than a stock with a beta of less than one.

Simply Wall St -

How Financially Strong Is Read-Gene SA (WSE:RDG)?

However, it also faces higher cost of capital given interest cost is generally lower than equity. … Is RDG right in choosing financial flexibility over lower cost of capital. … There are well-known benefits of including debt in capital structure, primarily a lower cost of capital

Simply Wall St -

Did Read-Gene SA (WSE:RDG) Create Value For Investors Over The Past Year?

and want to begin learning the link between Read-Gene SA (WSE:RDG)’s return fundamentals and stock market performance. … Read-Gene SA (WSE:RDG) generated a below-average return on equity of 1.31% in the past 12 months, while its industry returned 17.03%. … An investor may attribute an inferior ROE to a relatively inefficient performance, and whilst this can often be the case, knowing the nuts and bolts of the ROE calculation may change that perspective and give you a deeper insight into RDG's past performance

Simply Wall St -

How Read-Gene SA. (WSE:RDG) Delivered A Better ROE Than Its Industry

Return on Equity = Net Profit ÷ Shareholders Equity Returns are usually compared to costs to measure the efficiency of capital. … ROE can be dissected into three distinct ratios: net profit margin, asset turnover, and financial leverage. … This is called the Dupont Formula: Dupont Formula ROE = profit margin × asset turnover × financial leverage ROE = (annual net profit ÷ sales) × (sales ÷ assets) × (assets ÷ shareholders’ equity) ROE = annual net profit ÷ shareholders’ equity WSE:RDG Last Perf Apr 6th 18 Essentially, profit margin shows how much money the company makes after paying for all its expenses.

Simply Wall St -

RDG Company Info

Description

Read-Gene S.A. engages in the detection, prevention, and treatment of various types of malignant tumors. Its activities include chemoprevention, clinical trials, and genetic tests. Chemoprevention is the use of natural or synthetic substances to inhibit, reverse, or delay the process of developing cancer. The company conducts clinical trials in cancer patients; and provides genetic tests and genetic-oncological consultations to all patients for the most common cancers, such as breast, ovary, prostate, stomach, large intestine, and breast cancer. The company is based in Dobra, Poland. Read-Gene S.A. is a subsidiary of Gen-Pat-Med Sp. z o.o.

Details
Name: Read-Gene S.A.
RDG
Exchange: WSE
Founded:
PLN13,440,611
11,790,010
Website: http://www.read-gene.com
Address: Read-Gene S.A.
ul. Alabastrowa 8,
Grzepnica,
Dobra,
72-003,
Poland
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
WSE RDG Bearer Shares Warsaw Stock Exchange PL PLN 12. Feb 2009
Number of employees
Current staff
Staff numbers
0
Read-Gene employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/29 21:56
End of day share price update: 2020/03/27 00:00
Last earnings filing: 2019/11/14
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.